drugset
drugset / Trial / NCT04274738

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

NCT04274738 ↗

Phase 1 Completed 16 enrolled X4 Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of the study is to establish a pharmacologically active dose of mavorixafor in combination with ibrutinib based on pooled safety, clinical response, pharmacokinetic (PK) and pharmacodynamic (PD) data to select the recommended dose for a randomized registrations trial.

Timeline

Start
2020-04-30
Primary completion
2022-10-31
Completion
2022-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibrutinib Small molecule 420 mg Oral
Subject Mavorixafor Small molecule 200 mg Oral
Subject Mavorixafor Small molecule 400 mg Oral
Subject Mavorixafor Small molecule 600 mg Oral

Indications

Waldenstrom macroglobulinemia